StreetInsider.com News Articles

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Wed, 30 Sep 2026 16:05:00 -0400

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research

PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Wed, 30 Sep 2026 16:05:00 -0400

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research

Abivax (ABVX) PT Lowered to $151 at Truist Securities

Tue, 22 Sep 2026 07:15:26 -0400

Truist Securities analyst Greg Renza lowered the price target on Abivax (NASDAQ: ABVX) to $151.00 (from $155.00) while maintaining a Buy rating.

Form F-6EF Abivax S.A. Filed by: Citibank,N.A./ADR

Mon, 21 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260921/27085579.html

Form 6-K Abivax S.A. For: Jun 30

Mon, 21 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260921/27085478.html

Abivax Presents Business Updates and First Half 2026 Financial Results

Mon, 21 Sep 2026 16:05:00 -0400

Abivax Presents Business Updates and First Half 2026 Financial Results

Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions
Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029
Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax’s debt-free financial position

Abivax Presents Business Updates and First Half 2026 Financial Results

Mon, 21 Sep 2026 16:05:00 -0400

Abivax Presents Business Updates and First Half 2026 Financial Results

Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions

Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029

Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax’s debt-free financial position

This biotech stock has 'multiblockbuster IBD opportunity': analyst

Thu, 10 Sep 2026 17:00:00 -0400

Goldman Sachs has initiated coverage of a biotech name with a Buy rating in a note this week, describing the French company as a "multiblockbuster" opportunity in inflammatory bowel disease.
Abivax (NASDAQ: ABVX) is the stock in question. Analyst Rajan Sharma set 12-month price targets of €132 a share and $155 on the U.S.-listed shares, implying roughly 30% upside, well above the 15% average across the firm's European biotech coverage.
His positive view rests on Abivax's key pipeline asset, obefazimod, an ulcerative colitis therapy he sees as increasingly de-risked and capable of launching in the U.S. from 2027 with multibillion-dollar revenue

This biotech stock has 'multiblockbuster IBD opportunity': analyst

Thu, 10 Sep 2026 17:00:00 -0400

Goldman Sachs has initiated coverage of a biotech name with a Buy rating in a note this week, describing the French company as a "multiblockbuster" opportunity in inflammatory bowel disease.
Abivax (NASDAQ: ABVX) is the stock in question. Analyst Rajan Sharma set 12-month price targets of €132 a share and $155 on the U.S.-listed shares, implying roughly 30% upside, well above the 15% average across the firm's European biotech coverage.
His positive view rests on Abivax's key pipeline asset, obefazimod, an ulcerative colitis therapy he sees as increasingly de-risked and capable of launching in the U.S. from 2027 with multibillion-dollar revenue

Goldman Sachs Starts Abivax (ABVX) at Buy, 'screens well as a potential M&A target'

Thu, 10 Sep 2026 05:57:14 -0400
(Updated - September 10, 2026 5:57 AM EDT)
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ: ABVX) with a Buy rating and a price target of $155.00.
The analyst comments "We initiate coverage of Abivax with a Buy rating and 12m price targets of €132/ADR $155. Our positive view is underpinned by key pipeline asset obefazimod. With Phase 3 ulcerative colitis (UC) data in hand, we see the clinical pro le as de-risked with potential to address areas of unmet need in UC and a clear use case despite a competitive market. Whilst UC is the key driver of our

Goldman Sachs Starts Abivax (ABVX) at Buy, 'screens well as a potential M&A target'

Thu, 10 Sep 2026 05:57:14 -0400
(Updated - September 10, 2026 5:57 AM EDT)
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ: ABVX) with a Buy rating and a price target of $155.00.
The analyst comments "We initiate coverage of Abivax with a Buy rating and 12m price targets of €132/ADR $155. Our positive view is underpinned by key pipeline asset obefazimod. With Phase 3 ulcerative colitis (UC) data in hand, we see the clinical pro le as de-risked with potential to address areas of unmet need in UC and a clear use case despite a competitive market. Whilst UC is the key driver of our

Goldman Sachs Starts Abivax (ABVX) at Buy, 'screens well as a potential M&A target'

Thu, 10 Sep 2026 05:57:14 -0400
(Updated - September 10, 2026 5:57 AM EDT)
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ: ABVX) with a Buy rating and a price target of $155.00.
The analyst comments "We initiate coverage of Abivax with a Buy rating and 12m price targets of €132/ADR $155. Our positive view is underpinned by key pipeline asset obefazimod. With Phase 3 ulcerative colitis (UC) data in hand, we see the clinical pro le as de-risked with potential to address areas of unmet need in UC and a clear use case despite a competitive market. Whilst UC is the key driver of our

Goldman Sachs Starts Abivax (ABVX) at Buy, 'screens well as a potential M&A target'

Thu, 10 Sep 2026 05:57:14 -0400
(Updated - September 10, 2026 5:57 AM EDT)
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ: ABVX) with a Buy rating and a price target of $155.00.
The analyst comments "We initiate coverage of Abivax with a Buy rating and 12m price targets of €132/ADR $155. Our positive view is underpinned by key pipeline asset obefazimod. With Phase 3 ulcerative colitis (UC) data in hand, we see the clinical pro le as de-risked with potential to address areas of unmet need in UC and a clear use case despite a competitive market. Whilst UC is the key driver of our

Form SCHEDULE 13G/A Abivax S.A. Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260814/26931402.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260814/26931402.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260814/26931402.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 10:55:00 -0400
si-local-file:///var/storage/secattach/20260813/26918356.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 10:55:00 -0400
si-local-file:///var/storage/secattach/20260813/26918356.html

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 10:55:00 -0400
si-local-file:///var/storage/secattach/20260813/26918356.html

Abivax completes pre-NDA meeting with FDA for ulcerative colitis drug

Thu, 30 Jul 2026 16:07:24 -0400

Abivax SA (Nasdaq: ABVX) announced it has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for obefazimod, its drug candidate for the treatment of adults with moderately to severely active ulcerative colitis.
According to a statement from the company, the FDA provided feedback that resulted in alignment on the planned NDA submission strategy, including the content and format of the submission. Abivax said it remains on track to file its first NDA for obefazimod by the end of 2026.
Marc de Garidel, Chief Executive Officer of Abivax, said: "Achieving alignment with the FDA on our

Abivax completes pre-NDA meeting with FDA for ulcerative colitis drug

Thu, 30 Jul 2026 16:07:24 -0400

Abivax SA (Nasdaq: ABVX) announced it has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for obefazimod, its drug candidate for the treatment of adults with moderately to severely active ulcerative colitis.
According to a statement from the company, the FDA provided feedback that resulted in alignment on the planned NDA submission strategy, including the content and format of the submission. Abivax said it remains on track to file its first NDA for obefazimod by the end of 2026.
Marc de Garidel, Chief Executive Officer of Abivax, said: "Achieving alignment with the FDA on our

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Thu, 30 Jul 2026 16:05:00 -0400

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026

PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Thu, 30 Jul 2026 16:05:00 -0400

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026

PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Thu, 30 Jul 2026 16:05:00 -0400

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026

PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Thu, 30 Jul 2026 16:05:00 -0400

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026

PARIS, France – July 30, 2026 – 10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced